Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Hormony

Mexican menopause FemTech pairing saliva hormone kits with AI symptom tracking, already retailing in Hong Kong through Mannings pharmacies.

Chihuahua, Mexico, Latin AmericaHealthTech, FemTech – perimenopause / menopauseStartup World Cup Mexico 2026 (regional final in Chihuahua, 24 Sept. 2026)
Stage
UndeterminedAI integrated
Product
On the marketFirst customers
Funding raised
Undisclosedno funding
Founded
20233 years ago
Founders
1Mayra
Global score
4.5Grade DRank 63 of 151

Overview

Mexican FemTech founded by Mayra Hurtado Terminel that supports women through perimenopause and menopause. It already sells in Hong Kong (Mannings pharmacy chain).

Traction

First customers

Kit sold in Hong Kong through the Mannings pharmacy chain.

Market

Menopause market (treatments, supplements, products)

Perimenopause and menopause remain underdiagnosed and underserved, and women increasingly look for self-testing and digital support. Products are sold through pharmacies and e-commerce, and increasingly through clinicians who prescribe lifestyle or hormonal therapy. Buyers are mostly consumers, with pharmacies and clinics acting as channels. The category is growing but crowded, and differentiation is unclear.

Addressable market

2025
$18.7B
2030
$24.4B
+5.6% a year

Menopause market (treatments, supplements, products): $18.7bn in 2025, +5.6%/year, $24.4bn in 2030 (Grand View Research).

Customers

Women in perimenopause/menopause; pharmacies (Mannings); clinicians and women's-health programmes

Who signs the cheque

Consumers (out of pocket); pharmacy category managers; clinics

Geographies

  • Mexico
  • Hong Kong

Drivers

  • Growing awareness of menopause care
  • Self-testing and digital health adoption
  • Pharmacy retail interest in women's health

Headwinds

  • Weak differentiation
  • Limited clinical validation of saliva hormone testing (general caution)
  • Unknown volumes and funding

Grand View Research estimates the global menopause market at $18.7bn in 2025 (+5.6%/year to 2033), with the previous edition projecting $24.4bn in 2030.

Scalability 6/10. Women's health kits and products that can be replicated through pharmacies and e-commerce, but health registration and distribution must be negotiated country by country.

Market source: grandviewresearch.com

Technology

Category

FemTech – diagnostic kit plus digital app

AI integratedMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

A saliva hormone test kit is combined with digital tools and AI that track and interpret symptoms and results. The kit is sold in pharmacies.

Moat

Weak: distribution relationships (Mannings) and symptom data; testing technology is not proprietary as documented.

Differentiation

Combines at-home hormone testing with AI interpretation in one consumer journey.

Integration points

  • Pharmacy retail
  • Clinician lifestyle-medicine platforms
  • Women's-health diagnostics
  • Beauty/hair-care diagnostics

Depends on

  • Lab or test-kit supply
  • Health registration per country
  • Pharmacy partnerships

Use of AI

AI helps track and interpret symptoms and saliva hormone test results.

Product in detail

Saliva hormone test kit combined with digital tools and AI to track and interpret symptoms.

Business

Model
Kit sales through pharmacies plus digital services.
Revenue logic
Per-kit margin; potential subscription for tracking.
Go-to-market
Pharmacy distribution in Hong Kong; Mexican home base.

Next milestones

  1. Publish sales volumes
  2. Clinical validation study
  3. New pharmacy chain or clinic channel

Key risks

  • Undisclosed volumes
  • Differentiation
  • Regulatory registration per market

Opportunities

4 found in the network

Concrete moves for Hormony inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Co-development 2
  • Investors 1

Distribution1

A channel or customer base to reach together

Become the testing input for IKI's menopause lifestyle programmes

IKI Health lets clinicians prescribe personalised lifestyle programmes, notably for menopause, and needs patient data to personalise them. Hormony's kit and symptom tracker can feed that data, giving Hormony a clinician-led channel in Spain/Europe.

40%confidence

Evidence from the records

  • “lets healthcare professionals prescribe personalized lifestyle medicine programs (notably for menopause)”
  • “Saliva hormone test kit combined with digital tools and AI to track and interpret symptoms.”
If it works
A bundled clinician offer in Spain and a first European market.
First step
Propose to IKI a data-integration pilot with 50 patients.

Co-development2

An integration or joint product

Joint 'hair and hormones' campaign in Hong Kong

Hair thinning is a common menopause symptom and HairCoSys runs AI scalp diagnostics in Hong Kong salons. Cross-referrals between salons and Mannings pharmacies serve the same consumer.

35%confidence

Evidence from the records

  • “Tools used by salons in Hong Kong (Toni & Guy, fufu, Chalachol); rollout announced across the Powell Group's 70 salons.”
  • “Kit sold in Hong Kong through the Mannings pharmacy chain.”
If it works
Co-marketing reach in 70 salons and pharmacies.
First step
Contact HairCoSys's CEO to scope a joint promotion.

Share an at-home women's-health testing platform with Arelis

Arelis is developing an at-home urine test for endometriosis with ML analysis; Hormony runs at-home saliva testing with AI interpretation. Sharing the consumer app, sample logistics and pharmacy channels could reduce costs for both.

15%confidence

Evidence from the records

  • “Machine learning/AI analysis of a urine sample to build an endometriosis risk profile.”
  • “AI helps track and interpret symptoms and saliva hormone test results.”
If it works
A broader women's-health test portfolio for pharmacy partners.
First step
Arrange a founder call to explore a shared app/channel.

Investors1

A fund whose thesis fits

Pitch Innogen via Pulster.ai

Innogen invests at pre-seed/seed in Latin American HealthTech and is cited as a Pulster.ai investor in the network.

20%confidence

Evidence from the records

  • “Cacao Capital, MANA Tech (PitchBook); the site also cites Innogen Capital, Barrilete Ventures, Escala LATAM”
  • “Pharmacy distribution”
If it works
A LatAm seed investor to fund validation and expansion.
First step
Ask Pulster.ai's founders for an intro to Innogen.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Miami programme (Mana Common) helping Latin American Series A scale-ups enter the US via a 30-day track and Miami Immersion Week.

Mexican menopause femtech — US Hispanic women's health; stage undetermined.

35%confidence

Evidence from the records

  • “Latin American scale-ups enter the US market”
  • “FemTech – perimenopause / menopause”
  • “Kit sold in Hong Kong through the Mannings pharmacy chain.”
Intro path
Founder-to-founder intro via Pulster.ai (network portfolio company of Mana Tech).
First step
Clarify traction.

Investor with no profile in our data; invested an undisclosed amount in Spanish femtech/preventive health startup IKI Health.

Mexican menopause femtech — women's health.

30%confidence

Evidence from the records

  • “IKI Health”
  • “FemTech – perimenopause / menopause”
  • “Kit sold in Hong Kong through the Mannings pharmacy chain.”
Intro path
Founder-to-founder intro via IKI Health (network portfolio company of Max Ventures).
First step
Qualify via IKI Health.

Buenos Aires biotech fund and company builder backing pre-seed and seed Latin American life-science startups.

Mexican femtech for menopause — LatAm health, but consumer health rather than biotech.

25%confidence

Evidence from the records

  • “"Latin America"”
  • “FemTech – perimenopause / menopause”
  • “Kit sold in Hong Kong through the Mannings pharmacy chain.”
Intro path
Founder-to-founder intro via Nanogrow Biotech (network portfolio company of GridX).
First step
Only if Hormony develops a proprietary bio-based product.

Spain-based investor with an empty profile; its only recorded network deal is Argentine clinical-data marketplace Cromodata's pre-seed.

Mexican menopause FemTech selling in Hong Kong: Spanish-speaking founder in digital health, very thin evidence of Sancus fit.

15%confidence

Evidence from the records

  • “FemTech – perimenopause / menopause”
  • “Mexico”
First step
Low priority until Sancus's focus is known.

Investment analysis

4.5D

Grade D

Rank 63 of 151

Disruption4.0/10
Business model4.0/10
Market6.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Interesting distribution but insufficient evidence: too early.

Disruption

4/10

Menopause FemTech: a fast-growing category, but a weakly differentiated offer.

Business model

4/10

Kit sold in Hong Kong through Mannings, volumes not published.

Market

6/10

Score 6/10: TAM $18.7bn → base 5; scalability 6/10 (0); already sold in Mexico and Hong Kong (Mannings) (+1).

Risk

7/10

Lower is better

High risk: funding undetermined, limited information on the product.

Strengths

  • Pharmacy distribution
  • Growing FemTech market

Risks

  • Unclear differentiation
  • Unknown volumes

Funding

Undisclosed, no funding
  1. 2026

    prizenot specified

    1st place, Startup World Cup Mexico regional (Chihuahua Tech Week)

Amount used in the study. No funding round; regional prize not quantified.

Note. no public funding round found

Chihuahua regional confirmed (1st of 9 startups, Chihuahua Tech Week). Caution: the hormony.mx website is only a "Próximo lanzamiento" page; sales through Mannings (Hong Kong) are not cross-checked by Tiempo — to be monitored.

Team

  • Mayra Hurtado Terminel

    Founder

    Young entrepreneur from Chihuahua (Mexico), menopause FemTech.

Sources

Regional final
Startup World Cup Mexico 2026 (regional final in Chihuahua, 24 Sept. 2026)
Identification confidence
high
Founding year: 2023 (medium confidence)
Mayra Hurtado CEO since 02/06/2023 according to Descubre.vc (start proxy; operates via Prelude Health, Singapore) descubre.vc
  1. 1ecosistemastartup.com/hormony-gana-regional-mexico-de-startup-world-cup-2026/
  2. 2tiempo.com.mx/local/mayra-hurtado-startup-silicon-valley-chihuahua-2026/
  3. 3ecosistemastartup.com/hormony-startup-chihuahuense-gana-regional-de-startup-world
  4. 4hormony.mx/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet